The mechanism of cancer cell death by PARP inhibitors goes beyond DNA damage alone

Affiliations

¹ Department of Gynecologic Oncology, Azienda Ospedaliera Brotzu, Cagliari, Italy.
² Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.

Comment

Antonio Macciò et al. Int J Cancer. 2019.

. 2019 Nov 1;145(9):2594-2596.

doi: 10.1002/ijc.32392. Epub 2019 May 16.

¹ Department of Gynecologic Oncology, Azienda Ospedaliera Brotzu, Cagliari, Italy.
² Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.

No abstract available

Comment on

Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas.
Yi T, Feng Y, Sundaram R, Tie Y, Zheng H, Qian Y, You D, Yi T, Wang P, Zhao X. Yi T, et al. Int J Cancer. 2019 Sep 1;145(5):1209-1220. doi: 10.1002/ijc.32143. Epub 2019 Feb 23. Int J Cancer. 2019. PMID: 30666631

1. Yi T, Feng Y, Sundaram R, et al. Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas. Int J Cancer 2019. https://doi.org/10.1002/ijc.32143.
1. Jiang X, Li X, Li W, et al. PARP inhibitors in ovarian cancer: sensitivity prediction and resistance mechanisms. J Cell Mol Med 2019;23:2303-13.
1. Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010;376:245-51.
1. Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 2017;377:523-33.
1. Bang YJ, Xu RH, Chin K, et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2017;18:1637-51.